• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Moving Successful Virus-specific T-cell Therapy for Hematopoietic Stem Cell Recipients to Late Phase Clinical Trials.

作者信息

Rooney Cliona, Leen Ann

机构信息

1] Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital, Texas Children's Hospital, Houston, Texas, USA [2] Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA [3] Department of Pathology, Baylor College of Medicine, Houston, Texas, USA [4] Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA.

出版信息

Mol Ther Nucleic Acids. 2012 Nov 13;1(11):e55. doi: 10.1038/mtna.2012.49.

DOI:10.1038/mtna.2012.49
PMID:23629030
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3511676/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd5d/3511676/076c4055a810/mtna201249f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd5d/3511676/17ee5f49c4bd/mtna201249f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd5d/3511676/fc2e676bbad1/mtna201249f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd5d/3511676/076c4055a810/mtna201249f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd5d/3511676/17ee5f49c4bd/mtna201249f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd5d/3511676/fc2e676bbad1/mtna201249f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd5d/3511676/076c4055a810/mtna201249f3.jpg

相似文献

1
Moving Successful Virus-specific T-cell Therapy for Hematopoietic Stem Cell Recipients to Late Phase Clinical Trials.将针对造血干细胞接受者的成功的病毒特异性T细胞疗法推进到后期临床试验阶段。
Mol Ther Nucleic Acids. 2012 Nov 13;1(11):e55. doi: 10.1038/mtna.2012.49.
2
Late-phase human herpesvirus 6B reactivation in hematopoietic stem cell transplant recipients.造血干细胞移植受者中人类疱疹病毒6B的晚期再激活
Transpl Infect Dis. 2018 Aug;20(4):e12916. doi: 10.1111/tid.12916. Epub 2018 Jun 13.
3
Hepatitis B virus among hematopoietic stem cell transplant recipients: Antiviral impact in seroconversion, engraftment, and mortality in a Latin American center.造血干细胞移植受者中的乙型肝炎病毒：拉丁美洲某中心抗病毒治疗对血清学转换、植入和死亡率的影响
Transpl Infect Dis. 2020 Apr;22(2):e13243. doi: 10.1111/tid.13243. Epub 2020 Jan 13.
4
Reconstitution of Human Cytomegalovirus-Specific CD4+ T Cells is Critical for Control of Virus Reactivation in Hematopoietic Stem Cell Transplant Recipients but Does Not Prevent Organ Infection.人巨细胞病毒特异性CD4+ T细胞的重建对于控制造血干细胞移植受者的病毒再激活至关重要，但不能预防器官感染。
Biol Blood Marrow Transplant. 2015 Dec;21(12):2192-2202. doi: 10.1016/j.bbmt.2015.08.002. Epub 2015 Aug 8.
5
Unique BK virus non-coding control region (NCCR) variants in hematopoietic stem cell transplant recipients with and without hemorrhagic cystitis.有或无出血性膀胱炎的造血干细胞移植受者中独特的BK病毒非编码控制区（NCCR）变异体
J Med Virol. 2006 Apr;78(4):485-93. doi: 10.1002/jmv.20566.
6
Autologous Adoptive T-cell Therapy for Recurrent or Drug-resistant Cytomegalovirus Complications in Solid Organ Transplant Recipients: A Single-arm Open-label Phase I Clinical Trial.自体过继性 T 细胞疗法治疗实体器官移植受者复发性或耐药性巨细胞病毒并发症：一项单臂开放标签 I 期临床试验。
Clin Infect Dis. 2019 Feb 1;68(4):632-640. doi: 10.1093/cid/ciy549.
7
Epigenetic programming of T cells impacts immune reconstitution in hematopoietic stem cell transplant recipients.T 细胞的表观遗传编程影响造血干细胞移植受者的免疫重建。
Blood Adv. 2018 Mar 27;2(6):656-668. doi: 10.1182/bloodadvances.2018015909.
8
Late diversification in the clonal composition of human cytomegalovirus-specific CD8+ T cells following allogeneic hemopoietic stem cell transplantation.异基因造血干细胞移植后人类巨细胞病毒特异性CD8 + T细胞克隆组成的晚期多样化。
Blood. 2003 Nov 1;102(9):3427-38. doi: 10.1182/blood-2002-12-3689. Epub 2003 Jul 17.
9
Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity.异基因造血干细胞移植受者的晚期巨细胞病毒病及死亡率：病毒载量和T细胞免疫的重要性
Blood. 2003 Jan 15;101(2):407-14. doi: 10.1182/blood-2002-03-0993. Epub 2002 Sep 12.
10
The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of care.现在是时候了：在异基因造血干细胞移植后，将针对病毒的 T 细胞作为标准治疗方法。
Cytotherapy. 2014 Feb;16(2):149-59. doi: 10.1016/j.jcyt.2013.11.010.

引用本文的文献

1
Adoptive Cell Therapy for T-Cell Malignancies.T细胞恶性肿瘤的过继性细胞疗法
Cancers (Basel). 2022 Dec 23;15(1):94. doi: 10.3390/cancers15010094.
2
Genetically modified T cells in cancer therapy: opportunities and challenges.癌症治疗中的基因改造T细胞：机遇与挑战
Dis Model Mech. 2015 Apr;8(4):337-50. doi: 10.1242/dmm.018036. Epub 2015 Apr 1.
3
Pan-viral-microRNA screening identifies interferon inhibition as a common function of diverse viruses.全病毒微小RNA筛选确定干扰素抑制是多种病毒的共同功能。

本文引用的文献

1
Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation.异基因造血细胞移植后，采用未经选择或 EBV 特异性 T 细胞进行活检证实的 EBV+淋巴瘤的过继免疫治疗。
Blood. 2012 Mar 15;119(11):2644-56. doi: 10.1182/blood-2011-08-371971. Epub 2011 Dec 2.
2
Changing epidemiology of respiratory viral infections in hematopoietic cell transplant recipients and solid organ transplant recipients.造血细胞移植受者和实体器官移植受者中呼吸道病毒感染的流行病学变化。
Curr Opin Infect Dis. 2011 Aug;24(4):333-43. doi: 10.1097/QCO.0b013e3283480440.
3
Proc Natl Acad Sci U S A. 2015 Feb 10;112(6):1856-61. doi: 10.1073/pnas.1417891112. Epub 2015 Jan 26.
4
Identification and HLA-tetramer-validation of human CD4+ and CD8+ T cell responses against HCMV proteins IE1 and IE2.人类针对巨细胞病毒（HCMV）蛋白IE1和IE2的CD4+和CD8+T细胞应答的鉴定及HLA四聚体验证
PLoS One. 2014 Apr 23;9(4):e94892. doi: 10.1371/journal.pone.0094892. eCollection 2014.
5
Antiviral cell therapy: is this the future?抗病毒细胞疗法：这是未来的趋势吗？
Blood. 2013 Jun 27;121(26):5108-9. doi: 10.1182/blood-2013-05-500082.
Generation of multivirus-specific T cells to prevent/treat viral infections after allogeneic hematopoietic stem cell transplant.
产生多病毒特异性T细胞以预防/治疗异基因造血干细胞移植后的病毒感染。
J Vis Exp. 2011 May 27(51):2736. doi: 10.3791/2736.
4
Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation.采用链霉亲和素选择的巨细胞病毒特异性 CD8+ T 细胞过继转移和选择性重建可导致异基因外周血造血干细胞移植后患者的病毒清除。
Transfusion. 2011 Mar;51(3):591-9. doi: 10.1111/j.1537-2995.2010.02940.x. Epub 2010 Dec 6.
5
Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes.采用第三方 EBV 特异性细胞毒性 T 淋巴细胞对 EBV 相关移植后淋巴瘤进行成功治疗，该患者为脐带血移植后。
Blood. 2010 Dec 2;116(23):5045-9. doi: 10.1182/blood-2010-04-281873. Epub 2010 Sep 8.
6
Allogeneic T-cell therapy for Epstein-Barr virus-positive posttransplant lymphoproliferative disease: long-term follow-up.异基因T细胞疗法治疗爱泼斯坦-巴尔病毒阳性移植后淋巴细胞增生性疾病：长期随访
Transplantation. 2010 Jul 15;90(1):93-4. doi: 10.1097/TP.0b013e3181d7c424.
7
Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex).使用透气快速扩增培养器（G-Rex）加速用于临床前和临床应用的抗原特异性 T 细胞的生产。
J Immunother. 2010 Apr;33(3):305-15. doi: 10.1097/CJI.0b013e3181c0c3cb.
8
Prospective, comprehensive, and effective viral monitoring in children undergoing allogeneic hematopoietic stem cell transplantation.对接受异基因造血干细胞移植的儿童进行前瞻性、全面和有效的病毒监测。
Biol Blood Marrow Transplant. 2010 Oct;16(10):1428-35. doi: 10.1016/j.bbmt.2010.04.008. Epub 2010 Apr 24.
9
Challenges of T cell therapies for virus-associated diseases after hematopoietic stem cell transplantation.造血干细胞移植后病毒相关性疾病的 T 细胞治疗的挑战。
Expert Opin Biol Ther. 2010 Mar;10(3):337-51. doi: 10.1517/14712590903456003.
10
Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells.肽段选择的 T 细胞移植后对 EBV-PTLD 的有效和长期控制。
Blood. 2010 Apr 8;115(14):2960-70. doi: 10.1182/blood-2009-08-236356. Epub 2010 Jan 26.